CLINICAL TRIALS IN RETT SYNDROME A Mini-Symposium Chicago, June 22-23, 2008 Organized by: RettSearch Sponsored by: International Rett Syndrome Foundation.

Slides:

Advertisements

Similar presentations

A Brief Intervention Using a Web-based Patient Self Management Assessment Tool Improves Blood Glucose Control (HbA1c) Garry Welch, PhD1 Sofija Zagarins,

Advertisements

Center for Innovative the Begun Center for Violence Prevention Research and Education 1.

PARTNERSHIPS Keys for Surviving the Health Care Shortages.

Evdokia Anagnostou, MD Clinician Scientist, Holland Bloorview Kids Rehab Hospital Associate Professor, Department of Pediatrics University of Toronto Canada.

Early Infant Diagnosis: Challenges and Solutions A special session IAS, Vienna 2010.

ACCELERATING CLINICAL AND TRANSLATIONAL RESEARCH Anantha Shekhar MD, PhD Indiana University School of Medicine Indiana Clinical and.

NCI Designation: Expanding Science and Promoting Health in the Region Name Title, Company Date.

Influencing Change in Research, Treatment Protocols, and New Drug Development.

Our Mission Community Outreach for Youth & Family Services, Inc. is dedicated to improving the quality of life for both the youth and adult population.

State of the Region Overview of APR Data for the Western Region Western Regional Resource Center APR Clinic 2010 November 1-3, 2010 San Francisco, California.

Community Research Workshop - CRWIII Friday, February 17, 2012 Korean American Community Services.

The Use of Clinical Guidelines for Education Efforts in the Academic Setting.

Academic Clinical Trial Do’s & Don’ts for Partnering with Pharma CCAF San Diego, CA April 14, 2014 J. Eric Bubbers, Ph.D.

Urban Coalition for HIV Prevention Services (UCHAPS) SF HIV Prevention Planning Group November 9, 2006.

Acute Ischemic Stroke Management: 2004 Emergency Medicine Perspectives.

Howard Fillit, MD Executive Director Improving Animal Trials for Alzheimer’s Disease: Recommendations for Best Practices.

COMMUNITY OF PRACTICE SESSION STEM Education: Communication Tools and Collaboration Opportunities May 20, /20/11Superintendents Community of Practice.

(Title of Presentation) (Subtitle of Presentation) August 8, 2007 Hematologic Cancers Partners Meeting Centers for Disease Control and Prevention May 16,

CONCEPT 1. Grant $3.2 million 5-year grant Awarded by the Administration for Children and Families 55 Applicants – CT 1 of 5 States Nationally ◦ Selection.

OSU: Our Flagship Partner Jeff Nelson President 3/24/12.

Building Community Partnerships to Serve Immigrant Workers Funded by the Ford Foundation Nonprofit and Community College Collaborations.

Conducting Community Health Research

Newborn Screening Translational Research Network Coordinating Center Duane Alexander, M.D. Director, Eunice Kennedy Shriver National Institute of Child.

Effects of Pediatric Asthma Education on Hospitalizations and Emergency Department Visits: A Meta-Analysis June 3, 2007 Janet M. Coffman, PhD, Michael.

1 Michael V. Novinski President and Chief Executive Officer November 6, 2008 Third Quarter 2008 Earnings Conference Call.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

1) recommend best (preclinical) practices for efficiently evaluating and developing agents in the CMCR pipeline for possible applications in cancer patients.

Overview & Brief Introductions Jon F. Kerner, Ph.D. Division of Cancer Control & Population Sciences Lenora Johnson, M.P.H., C.H.E.S. Center for Strategic.

Drug and Alcohol Treatment for offenders – What Works? Mike Trace Chief Executive RAPt (Rehabilitation of Addicted Prisoners Trust)

An Overview of Mental Health and Children Abram Rosenblatt, Ph.D. University of California, San Francisco.

1 Agenda Kauffman’s strategy for entrepreneurship Judges’ recommendations for final proposals Group Q & A Lunch.

Evaluation Highlights from Pilot Phase July 2005 – June 2007 Prepared for Leadership Team Meeting January 11, 2008.

April 2005 How Patients Can Benefit From Molecular Imaging Paula M. Jacobs, Ph.D Vice President Advanced Magnetics, Inc.

Study Design Overview and lessons learned Alan Percy, MD JUNE 23, 2008 RETT SYNDROME CLINICAL TRIALS MINI-SYMPOSIUM.

WORKING TOGETHER FOR KIDS MENTAL HEALTH. IMPLEMENTATION Working Together for Kids Mental Health is being implemented in four communities during 2010/11:

Building Bridges and Pathways to College and Careers Linda Collins Executive Director CLP January 24, 2008.

Principles and Practices: The implementation of ethical guidelines for research on HIV Geneva, 2-3 June 2003 Ethical guidelines for HIV vaccines: Generic.

Databases Using them to study MS in the UK. Proposed research using: GPRD (General Practice Research Database) MSNTC Northwood Database.

Cure CMD 2010 CMD Family Conference Mission & Goals Roadmap Treatment.

Medication Therapy Management Programs in Community Pharmacy Community Pharmacy October 17, 2006 Kurt A. Proctor, Ph.D., RPh Chief Operating Officer Community.

Addiction Treatment in Israel: An Overview of Services Provision Iris Mordecovitch, MSW.

Walter E. Kaufmann, M.D. Kennedy Krieger Institute/Johns Hopkins University SCALES AS OUTCOME MEASURES CLINICAL TRIALS IN RETT SYNDROME A Mini-Symposium.

The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.

The Dementia HIT: Who we are and what we do Dr Liz Coulthard.

Stratifying RTT Patients for Clinical Trials A Mutation Based Approach

Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.

C-1 Pegfilgrastim (Neulasta  ) Oncologic Drugs Advisory Committee Pediatric Subcommittee October 20, 2005 Amgen Inc.

Massachusetts Cancer Prevention Community Research Network (MCPCRN) CPCRN Atlanta Meeting October 15-16, 2009.

TRUST STATUS. The National Context 2006 Education and Inspections Act: Empowering schools - autonomy / self-governance (Foundation Status) All schools.

Cancer Genetic Counseling and Familial Cancer Risk Assessment Program Zohra Ali-Khan Catts, MS LCGC Helen F. Graham Cancer Center Christiana Care Health.

Patient Engagement throughout the Biopharmaceutical Lifecycle: Tips for Effective Patient Advocate/Industry Collaboration to Improve Patient Access and.

Saint Alphonsus Research Assets and Opportunities Timothy E. Sawyer, MD Radiation Oncologist Medical Director, Saint Alphonsus Cancer Care Center Founder,

New Horizons for SMA.

Michael Nawrocki, Vice President of Technology and Solutions ATIS

Pharmaceutical- vs Dispensary-Sourced Cannabinoids

Changing the IBD Paradigm

Hunter Syndrome: Why We Need to Diagnose and Treat Early

Optimizing Patient Outcomes in IBD

An Approach to Standard Programming in a Clinical Data Repository

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

Postpartum Depression

PCSK9 Inhibitors and Cardiovascular Outcomes

Immunotherapy for cSCC

Best Practices in the Clinical Management of Motor Symptoms Associated With Huntington Disease.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Prostacyclin Pathway Agents in Action

Figure 3 Rett syndrome severity and age at diagnosis by mutation type

PICO model for developing EBM questions

Binge Eating Disorder.

Anti-epileptic drugs with Na+ channel blocking activity improve QTc in individuals with Rett syndrome. Anti-epileptic drugs with Na+ channel blocking activity.

Presentation transcript:

CLINICAL TRIALS IN RETT SYNDROME A Mini-Symposium Chicago, June 22-23, 2008 Organized by: RettSearch Sponsored by: International Rett Syndrome Foundation

CLINICAL TRIALS IN RETT SYNDROME A Mini-Symposium Chicago, June 22-23, 2008 CONTEXT 1.Follow up of 2006 San Francisco meeting was needed for discussing multi-center initiatives and the future of RettSearch. 2.The Rett community is growing: new clinics and more scientists (opportunities for translational research). 3.Merge of IRSA and RSRF into IRSF provided opportunity. IRSF is committed to patient-based research. 4.Mini-symposium format allows the identification of key issues. Next meeting will be expanded. 5.Potential industry partners and new clinic centers are present.

CLINICAL TRIALS IN RETT SYNDROME A Mini-Symposium Chicago, June 22-23, 2008 GOALS 1.To determine where we are in terms of: a)Carrying out multi-center RTT clinical trials. b)Introducing new therapies for RTT. 2.To develop a document stating the meeting’s: a)Conclusions (diagnosis). b)Recommendations (treatment). 3.To publish Conclusions & Recommendations of meeting and full-length? papers (J Child Neurol).

CLINICAL TRIALS IN RETT SYNDROME A Mini-Symposium Chicago, June 22-23, 2008 AGENDA 1.Target population: who should be treated? a)Genotype-phenotype correlations b)Natural history studies 2.Outcome targets: what to measure? a)Rating scales b)Other measures 3.Treatment targets: what to use? a)Prior experiences. b)New and promising therapeutic agents.